Abbott India Ltd vs Alivus Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Abbott India Ltd is ₹ 25700 as of 04 May 09:39 . The P/E Ratio of Abbott India Ltd changed from 46.1 on March 2021 to 46.2 on March 2025 . This represents a CAGR of 0.04% over 5 yearsThe P/E Ratio of Alivus Life Sciences Ltd changed from 13.4 on March 2022 to 27.2 on March 2025 . This represents a CAGR of 19.36% over 4 years The Market Cap of Abbott India Ltd changed from ₹ 31850 crore on March 2021 to ₹ 65302 crore on March 2025 . This represents a CAGR of 15.44% over 5 yearsThe Market Cap of Alivus Life Sciences Ltd changed from ₹ 5624 crore on March 2022 to ₹ 13229 crore on March 2025 . This represents a CAGR of 23.84% over 4 years The revenue of Abbott India Ltd for the Dec '25 is ₹ 1793 crore as compare to the Sep '25 revenue of ₹ 1827 crore. This represent the decline of -1.82% The revenue of Alivus Life Sciences Ltd for the Dec '25 is ₹ 686.82 crore as compare to the Sep '25 revenue of ₹ 602.7 crore. This represent the growth of 13.96% The ebitda of Abbott India Ltd for the Dec '25 is ₹ 533.23 crore as compare to the Sep '25 ebitda of ₹ 572.12 crore. This represent the decline of -6.8% The ebitda of Alivus Life Sciences Ltd for the Dec '25 is ₹ 219.54 crore as compare to the Sep '25 ebitda of ₹ 193.89 crore. This represent the growth of 13.23% The net profit of Abbott India Ltd changed from ₹ 328.01 crore to ₹ 375.96 crore over 7 quarters. This represents a CAGR of 8.11% The net profit of Alivus Life Sciences Ltd changed from ₹ 111.48 crore to ₹ 150.26 crore over 7 quarters. This represents a CAGR of 18.60% The Dividend Payout of Abbott India Ltd changed from 84.61 % on March 2021 to 71.36 % on March 2025 . This represents a CAGR of -3.35% over 5 yearsThe Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 12.62 % on March 2025 . This represents a CAGR of -32.68% over 4 years .

About Abbott India Ltd

Abbott India Limited was originally incorporated on August 22, 1944 as Boots Pure Drug Company (India) Limited.
The company name was changed to 'The Boots Company (India) Limited' on November 1, 1971, thereafter to Boots Pharmaceuticals Limited on January 1, 1991.
In October, 1995 the name was changed to Knoll Pharmaceuticals Limited, and in July, 2002, they got their present name 'Abbott India Limited'. Company is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country.
The Company sells its products through independent distributors primarily within India.
It provides products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc.

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

FAQs for the comparison of Abbott India Ltd and Alivus Life Sciences Ltd

Which company has a larger market capitalization, Abbott India Ltd or Alivus Life Sciences Ltd?

Market cap of Abbott India Ltd is 54,040 Cr while Market cap of Alivus Life Sciences Ltd is 12,733 Cr

What are the key factors driving the stock performance of Abbott India Ltd and Alivus Life Sciences Ltd?

The stock performance of Abbott India Ltd and Alivus Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Abbott India Ltd and Alivus Life Sciences Ltd?

As of May 4, 2026, the Abbott India Ltd stock price is INR ₹25430.9. On the other hand, Alivus Life Sciences Ltd stock price is INR ₹1037.5.

How do dividend payouts of Abbott India Ltd and Alivus Life Sciences Ltd compare?

To compare the dividend payouts of Abbott India Ltd and Alivus Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.